JPM-OEt is a broad-spectrum inhibitor of cysteine cathepsins, exhibiting antitumor activity by covalently and irreversibly binding to the active site of cysteine cathepsin family members; it significantly reduces tumor cathepsin B activity, induces tumor regression in the RIP1-Tag2 (RT2) mouse model of pancreatic islet cell tumorigenesis, and causes a significant delay in the increase of tumor burden during the first two weeks of treatment.